Contents of madical intervention for each grade>2 adverse events with highest incidence in 18 months.

Figshare2015-12-02 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/_Contents_of_madical_intervention_for_each_grade_gt_2_adverse_events_with_highest_incidence_in_18_months_/1281556 数据链接链接失效反馈

官方服务：

资源简介：

Contents of madical intervention for each grade>2 adverse events with highest incidence in 18 months.

创建时间：

2015-12-02

DataSheet_1_Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.pdf

尿路上皮癌

药物不良事件管理

Cisplatin-based chemotherapy has been the standard of care for patients with locally advanced or metastatic urothelial cancer (la/mUC). Enfortumab vedotin, an antibody-drug conjugate directed to Necti

NIAID Data Ecosystem10

Dataset from A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis

多发性硬化症治疗

药物不良事件管理

The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF [Tecfidera])-related gast

NIAID Data Ecosystem00

Dataset from A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib

甲状腺髓样癌

药物不良事件管理

The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with

NIAID Data Ecosystem00

Supplementary Material for: Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer

甲状腺癌药物

药物不良事件管理

Objectives: Effective management of adverse events (AEs) following vandetanib treatment is important to maximize clinical benefits. We examined whether more frequent contact with vandetanib-treated pa

Figshare2016-09-12 更新00

A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis

多发性硬化症治疗

药物不良事件管理

DataCite Commons2025-02-10 更新00